keyword
MENU ▼
Read by QxMD icon Read
search

ZES

keyword
https://www.readbyqxmd.com/read/28097810/physicochemical-and-biological-evaluation-of-a-cinnamamide-derivative-r-s-2e-1-3-hydroxypiperidin-1-yl-3-phenylprop-2-en-1-one-km-608-for-nervous-system-disorders
#1
Agnieszka Gunia-Krzyżak, Ewa Żesławska, Florence Bareyre, Wojciech Nitek, Anna M Waszkielewicz, Henryk Marona
A cinnamamide scaffold has been successfully incorporated in several compounds possessing desirable pharmacological activities in central and peripheral nervous system such as anticonvulsant, antidepressant, neuroprotective, analgesic, anti-inflammatory, muscle relaxant, and sedative/hypnotic properties. R,S-(2E)-1-(3-hydroxypiperidin-1-yl)-3-phenylprop-2-en-1-one (KM-608), a cinnamamide derivative, was synthesized, its chemical structure was confirmed by means of spectroscopy and crystallography, additionally thermal analysis showed that it exists in one crystalline form...
January 18, 2017: Chemical Biology & Drug Design
https://www.readbyqxmd.com/read/28062139/efficacy-and-safety-of-everolimus-and-zotarolimus-eluting-stents-versus-first-generation-drug-eluting-stents-in-patients-with-diabetes-a-meta-analysis-of-randomized-trials
#2
Chirag Bavishi, Usman Baber, Sadik Panwar, Stefania Pirrotta, George D Dangas, Pedro Moreno, Jacqueline Tamis-Holland, Annapoorna S Kini, Samin K Sharma
INTRODUCTION: Patients with diabetes and coronary artery disease remain at high risk for adverse cardiovascular events after percutaneous coronary intervention. The efficacy and safety of the various drug-eluting stents (DES) in patients with diabetes is unclear. METHODS: Randomized controlled trials comparing first-generation DES [paclitaxel-eluting stents (PES) and sirolimus-eluting stents (SES)] with everolimus-eluting stents (EES) and zotarolimus-eluting stents (ZES) in diabetic patients were systematically searched...
December 27, 2016: International Journal of Cardiology
https://www.readbyqxmd.com/read/28058079/zollinger-ellison-syndrome-a-rare-case-of-chronic-diarrhea
#3
Ali Aamar, Kamraan Madhani, Hafeezulhassan Virk, Zeeshan Butt
Zollinger-Ellison syndrome (ZES) is caused by hypersecretion of gastrin from duodenal or pancreatic gastrinomas. We report a case of a 57-year-old female who presented with chronic diarrhea. CT abdomen showed multiple liver masses. Liver biopsy suggested metastatic well-differentiated neuroendocrine tumor. Serum gastrin level was markedly elevated. MRI abdomen, somatostatin receptor scintigraphy and endoscopic ultrasound failed to reveal primary site of the tumor. Upper gastrointestinal endoscopy showed hyperplastic gastric folds and multiple duodenal ulcers consistent with ZES...
December 2016: Gastroenterology Research
https://www.readbyqxmd.com/read/28034576/comparison-of-angioscopic-findings-among-second-generation-drug-eluting-stents
#4
Yuji Nishimoto, Yasunori Ueda, Ryuta Sugihara, Ayaka Murakami, Keisuke Ueno, Yasuharu Takeda, Akio Hirata, Kazunori Kashiwase, Yoshiharu Higuchi, Yoshio Yasumura
BACKGROUND: First-generation drug-eluting stents (DES) have reduced short-term stent failure as compared to bare-metal stents due to the inhibition of neointima hyperplasia, but instead increased the risk of very-late stent failure. Although better outcomes have been reported for second-generation DES than for first-generation DES, the difference in the angioscopic findings at 1-year follow-up has not been adequately elucidated among second-generation DES. METHODS: Consecutive 161 patients who received angioscopic examination at 1 year after implantation of second-generation DES, i...
December 26, 2016: Journal of Cardiology
https://www.readbyqxmd.com/read/28028304/zollinger-ellison-syndrome-an-unusual-case-of-chronic-diarrhoea-in-a-child
#5
R Goyal, U Debi, P Dey, K K Prasad, B R Thapa
Most cases of Zollinger-Ellison syndrome (ZES) are described in adults. It is a rare disorder in childhood. Most cases present with abdominal pain due to peptic ulceration and chronic diarrhoea not responding to general measures. The symptom complex is initially confused with other more common diseases, which lead to a delay in diagnosis. We present a rare case of a-12-year boy who initially presented with abdominal pain, diarrhoea, vomiting and progressive weight loss for over a two-year period before he was finally diagnosed as a case of ZES with the primary tumour in the pancreatic head and with multiple metastasis in both the liver and lymph nodes...
December 2016: Malaysian Journal of Pathology
https://www.readbyqxmd.com/read/28017259/zotarolimus-eluting-resolute-integrity-versus-everolimus-eluting-xience-xpedition-stents-in-the-management-of-very-long-30mm-de-novo-coronary-artery-stenosis
#6
Soumya Patra, Rabindra Nath Chakraborty, Arindam Pande, Suvro Banerjee, Manabhanjan Jena, Prakash Chandra Mandal, Swapan Kumar De, Aftab Khan, Sankha Suvro Das, Debashish Ghosh, Raja Nag
BACKGROUND: Procedural and clinical outcomes in patients with very long (>30mm) coronary lesions who underwent stent-based percutaneous coronary interventions are still unfavorable. Therefore, we compared the relative efficacy and safety of resolute zotarolimus-eluting stents (R-ZES) and Xpedition everolimus-eluting stents (X-EES) for patients with de novo very long coronary lesions. METHODS: This comparative single-centre, retrospective study compared long R-ZES and X-EES in consecutive patients admitted with very long (≥30mm) native ACC/AHA type C coronary lesions in 2014...
December 15, 2016: Cardiovascular Revascularization Medicine: Including Molecular Interventions
https://www.readbyqxmd.com/read/27916746/three-year-safety-and-efficacy-of-treating-all-comers-with-newer-generation-resolute-integrity-or-promus-element-stents-in-the-randomised-dutch-peers-twente-ii-trial
#7
Liefke C van der Heijden, Marlies M Kok, Marije M Löwik, Peter W Danse, Gillian A J Jessurun, Raymond W M Hautvast, K Gert van Houwelingen, Martin G Stoel, Marc Hartmann, Gerard C Linssen, Carine J M Doggen, Clemens von Birgelen
AIM: To assess the 3-year safety and efficacy of implanting newer-generation Resolute Integrity zotarolimus-eluting stents (ZES) versus Promus Element everolimus-eluting stents (EES) in all-comers. METHODS AND RESULTS: In the randomised, multi-center, investigator-initiated DUTCH PEERS trial, a total of 1,811 all-comers were 1:1 randomly assigned to treatment with ZES versus EES. A total of 1,293 patients (72%) were treated for complex lesions and 455 patients (25%) were treated for multiple lesions...
December 6, 2016: EuroIntervention
https://www.readbyqxmd.com/read/27876250/structure-anticonvulsant-activity-studies-in-the-group-of-e-n-cinnamoyl-aminoalkanols-derivatives-monosubstituted-in-phenyl-ring-with-4-cl-4-ch3-or-2-ch3
#8
Agnieszka Gunia-Krzyżak, Dorota Żelaszczyk, Anna Rapacz, Ewa Żesławska, Anna M Waszkielewicz, Katarzyna Pańczyk, Karolina Słoczyńska, Elżbieta Pękala, Wojciech Nitek, Barbara Filipek, Henryk Marona
A series of twenty two (E)-N-cinnamoyl aminoalkanols derivatives monosubstituted in phenyl ring with 4-Cl, 4-CH3 or 2-CH3 was designed, synthesized and evaluated for anticonvulsant activity in rodent models of seizures: maximal electroshock (MES) test, subcutaneous pentylenetetrazole (scPTZ) test, and 6-Hz test. There were identified three most active compounds: S-(2E)-N-(1-hydroxypropan-2-yl)-3-(2-methylphenyl)prop-2-enamide (5) (ED50 MES=42.56, ED50 scPTZ=58.38, ED50 6-Hz 44mA=42.27mg/kg tested in mice after intraperitoneal (i...
January 15, 2017: Bioorganic & Medicinal Chemistry
https://www.readbyqxmd.com/read/27866130/outcomes-of-stenting-extra-small-%C3%A2-2-25-mm-vessels-using-the-resolute-zotarolimus-eluting-stent-r-zes
#9
Manish A Parikh, Jonathan Soverow, Martin B Leon, Patrick Serruys, Bo Xu, Zuyi Yuan, Robayaah Zambahari, Ajay Kirtane
AIMS: We assessed long-term outcomes in patients with extra-small (XS) (≤2.25 mm) and small vessels (SV) (>2.25-2.75 mm) treated with the Resolute zotarolimus-eluting stent (R-ZES). METHODS AND RESULTS: Data from eight studies including patients with XS or SV were pooled for this analysis. Among 2,141 patients (837 XS, 1,304 SV), three-year cumulative major adverse cardiac events (15.4% vs. 11.5%; adj. HR [95% CI]: 1.3 [1.0, 1.7], p=0.12), target lesion failure (12...
November 20, 2016: EuroIntervention
https://www.readbyqxmd.com/read/27866129/long-term-outcomes-after-resolute-zotarolimus-eluting-stent-implantation-in-patients-with-st-segment-elevation-acute-myocardial-infarction-insights-from-the-resolute-all-comers-trial-and-the-resolute-global-clinical-trial-program
#10
Carlo Di Mario, Patrick W Serruys, Sigmund Silber, Shuzheng Lu, Weimin Wang, Petr Widimský, Bo Xu, Stephan Windecker
AIMS: We examined long-term outcomes after implantation of the Resolute zotarolimus-eluting stent (R-ZES) in ST-segment elevation acute myocardial infarction (STEMI) patients. METHODS AND RESULTS: We compared long-term outcomes of STEMI patients undergoing primary angioplasty <12 hours from symptom onset who were randomised to the R-ZES (n=122) or the everolimus-eluting stent (EES, n=158) in the RESOLUTE All Comers Trial after propensity score adjustment. The five-year cumulative incidence of target lesion failure (TLF) was 7...
November 20, 2016: EuroIntervention
https://www.readbyqxmd.com/read/27836296/long-term-comparative-effectiveness-of-paclitaxel-eluting-and-everolimus-eluting-stents-in-new-york
#11
Feng Qian, Ye Zhong, Edward L Hannan
OBJECTIVE: First generation paclitaxel-eluting stents (PES) and second generation everolimus-eluting stents (EES) were approved for use in percutaneous coronary interventions (PCIs) in 2004 and 2008, respectively. However, relative long-term outcomes of PES vs EES in real practice remain unclear. We sought to determine the long-term comparative effectiveness of PES vs EES using New York State (NYS) cardiac registries and to assess long-term outcomes of PES vs ZES in six "off-label" and two "high-risk" patient subgroups...
January 15, 2017: International Journal of Cardiology
https://www.readbyqxmd.com/read/27822890/comparison-of-the-endothelial-coverage-in-everolimus-and-zotarolimus-eluting-stents-in-normal-atherosclerotic-and-bifurcation-rabbit-iliac-arteries
#12
Sho Torii, Gaku Nakazawa, Takeshi Ijichi, Ayako Yoshikawa, Yohei Ohno, Yuji Ikari
The aim of this study is to evaluate differences in stent endothelial coverage among the second generation of drug-eluting stents. Incomplete stent coverage is one of the major causes of late stent thrombosis. Rabbits fed a normal diet received an everolimus (Xience Prime; EES) and a zotarolimus-eluting stent (Resolute Integrity; R-ZES) in each iliac artery, followed by sacrifice at 14 and 28 days after stent implantation. In addition, a group of atherosclerotic rabbits similarly received EES and R-ZES, and were sacrificed at 28 days...
November 7, 2016: Cardiovascular Intervention and Therapeutics
https://www.readbyqxmd.com/read/27773864/comparison-of-clinical-outcomes-after-multivessel-versus-single-vessel-stenting-with-the-zotarolimus-eluting-stent-in-the-resolute-global-clinical-trial-program
#13
Ganesh Manoharan, Jorge A Belardi, Zhimin Du, Michael Lee, Shubin Qiao, Patrick W Serruys, Stephan Windecker, Bo Xu, Alan Yeung
AIMS: To investigate whether long-term (3-year) clinical outcomes after multivessel treatment with the Resolute zotarolimus-eluting stent (R-ZES) were similar to single-vessel treatment. METHODS AND RESULTS: The RESOLUTE Global Clinical Trial Program enrolled 7618 patients, of whom 1562 underwent multivessel and 6053 single-vessel treatment with the R- ZES. Patients in the multivessel group were more likely to have complex lesions (58% vs 44%, p<0.001). Clinical outcomes were compared using a Cox regression model adjusted by propensity score to account for differences in baseline characteristics...
October 25, 2016: EuroIntervention
https://www.readbyqxmd.com/read/27761750/comparison-of-vascular-responses-after-different-types-of-second-generation-drug-eluting-stents-implantation-detected-by-optical-coherence-tomography
#14
Hirofumi Ohtani, Shigeki Kimura, Tomoyo Sugiyama, Keiichi Hishikari, Toru Misawa, Masafumi Mizusawa, Kazuto Hayasaka, Yosuke Yamakami, Keisuke Kojima, Yuichiro Sagawa, Hiroyuki Hikita, Takashi Ashikaga, Atsushi Takahashi, Mitsuaki Isobe
: Few studies have directly compared vascular responses to second-generation drug-eluting stents (DESs). We performed optical coherence tomography examinations in 56 consecutive patients with implanted single stent [19 cobalt-chromium everolimus-eluting stents (CoCr-EES), 22 platinum-chromium EES (PtCr-EES), and 15 resolute zotarolimus-eluting stents (R-ZES)] for de novo lesions, and who did not have restenosis at their 9-month follow-up. Neointimal thickness (NIT), stent apposition, and neointimal coverage were assessed in every strut...
October 19, 2016: International Journal of Cardiovascular Imaging
https://www.readbyqxmd.com/read/27634828/prospective-randomized-comparison-of-clinical-and-angiographic-outcomes-between-everolimus-eluting-vs-zotarolimus-eluting-stents-for-treatment-of-coronary-restenosis-in-drug-eluting-stents-intravascular-ultrasound-volumetric-analysis-restent-isr-trial
#15
Soon Jun Hong, Chul Min Ahn, Byeong-Keuk Kim, Young-Guk Ko, Seung-Ho Hur, Cheol Woong Yu, Seung-Jin Lee, Cheol Ung Choi, Je Sang Kim, Jung-Han Yoon, Young Joon Hong, Jae-Woong Choi, Seung-Hyuk Choi, Yangsoo Jang, Do-Sun Lim
AIMS: At present no proven standard treatment for drug-eluting stent (DES) restenosis is available, and the efficacy and safety of everolimus-eluting stent (EES) and zotarolimus-eluting stent (ZES) for DES restenosis are limited. The purpose of this prospective, randomized 9-month intracoronary ultrasound (IVUS) and 3-year clinical follow-up study was to compare the effects of EESs and ZESs on neointima volume and major adverse cardiovascular events (MACEs) such as death, myocardial infarction (MI), target lesion revascularization (TLR) and stent thrombosis in DES restenosis patients...
December 1, 2016: European Heart Journal
https://www.readbyqxmd.com/read/27570419/management-of-gastric-and-duodenal-neuroendocrine-tumors
#16
REVIEW
Yuichi Sato, Satoru Hashimoto, Ken-Ichi Mizuno, Manabu Takeuchi, Shuji Terai
Gastrointestinal neuroendocrine tumors (GI-NETs) are rare neoplasms, like all NETs. However, the incidence of GI-NETS has been increasing in recent years. Gastric NETs (G-NETs) and duodenal NETs (D-NETs) are the common types of upper GI-NETs based on tumor location. G-NETs are classified into three distinct subgroups: type I, II, and III. Type I G-NETs, which are the most common subtype (70%-80% of all G-NETs), are associated with chronic atrophic gastritis, including autoimmune gastritis and Helicobacter pylori associated atrophic gastritis...
August 14, 2016: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/27569387/frequency-of-stent-thrombosis-risk-at-5%C3%A2-years-in-women-versus-men-with-zotarolimus-eluting-compared-with-sirolimus-eluting-stent
#17
Monique Ten Haaf, Yolande Appelman, William Wijns, Gabriel Steg, Laura Mauri, Tessa Rademaker-Havinga, Gwenn Wetzels, Lisa Bousquette, Edoardo Camenzind, Eric Boersma
The prevalence of factors that are associated with an increased risk of stent thrombosis (ST), including smoking, diabetes mellitus, and small stent size, is different in women and men who underwent percutaneous coronary intervention. Thus, gender may potentially modify the relation between stent type and the incidence of ST during long-term follow-up. We explored the data of Patient Related Outcomes With Endeavor Versus Cypher stenting Trial (PROTECT) to evaluate this hypothesis. PROTECT randomized 2,061 women and 6,648 men who underwent percutaneous coronary intervention for various indications to Endeavor zotarolimus-eluting stenting (E-ZES) or Cypher sirolimus-eluting stenting (C-SES)...
October 15, 2016: American Journal of Cardiology
https://www.readbyqxmd.com/read/27520327/drug-induced-vitamin-b12-deficiency-a-focus-on-proton-pump-inhibitors-and-histamine-2-antagonists
#18
Lauren Linder, Cynthia Tamboue, Jennifer N Clements
OBJECTIVE: To review primary literature of gastric acid suppressive agents and vitamin B12 deficiency. DATA SYNTHESIS: From the published articles, proton pump inhibitors (PPIs) are associated with a higher risk of inducing vitamin B12 deficiency than histamine-2 receptor antagonists (H2RAs). Literature suggests that there is an increased risk of developing vitamin B12 deficiency in patients who are exposed to extended durations of therapy with PPIs. There are, however, some conflicting data in elderly patients suggesting that the PPI use for more than 3 years does not increase the risk of vitamin B12 deficiency...
August 12, 2016: Journal of Pharmacy Practice
https://www.readbyqxmd.com/read/27441483/long-term-follow-up-of-full-metal-jacket-of-de-novo-coronary-lesions-with-new-generation-zotarolimus-eluting-stents
#19
Alessandro Durante, Giovanni Foglia Manzillo, Francesco Burzotta, Carlo Trani, Cristina Aurigemma, Francesco Summaria, Roberto Patrizi, Giovanni Paolo Talarico, Azeem Latib, Filippo Figini, Enrico Romagnoli, Mariarosaria De Vita, Cecilia Fantoni, Luigi My, Claudio Larosa, Alessandro Manzoli, Maurizio Turturo, Andrea Berni, Giovanni Corrado
BACKGROUND: Diffuse coronary artery disease treatment still remains a challenge for interventional cardiologists and cardiac surgeons. There are few data on full metal jacket (FMJ) stenting, especially with new-generation drug-eluting stents. We aimed to assess the efficacy and safety of FMJ with new-generation Zotarolimus-eluting stents (n-ZES). METHODS AND RESULTS: All patients who underwent FMJ with n-ZES (≥60mm stent length) in eleven Italian interventional centers participating in the Clinical Service® project were included in this analysis...
October 15, 2016: International Journal of Cardiology
https://www.readbyqxmd.com/read/27434360/angioscopic-comparison-of-arterial-repair-after-second-generation-drug-eluting-stent-implantation-into-vulnerable-and-stable-coronary-plaques
#20
Kenji Kawai, Minoru Ichikawa, Tohru Masuyama, Yoshiyuki Kijima
BACKGROUND: Arterial repair after intracoronary stenting depends on stent types and plaque vulnerability. The aim of this study was angioscopic comparison of arterial repair after implantation of the second-generation drug-eluting stents (G2-DES) between the stable and vulnerable plaques. METHODS: Four types of G2-DES were successfully implanted into stable plaques (n=41) and vulnerable plaques (n=34): 13 and 9 Xience-everolimus-, 7 and 6 Endeavor-zotarolimus-, 15 and 9 Resolute-zotarolimus-, and 6 and 10 Nobori-biolimus-eluting stents (EES, E-ZES, R-ZES, and BES), respectively...
October 15, 2016: International Journal of Cardiology
keyword
keyword
17621
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"